Breast cancer poses a serious public health problem, and it is hoped that identification of
genetic and environmental factors that contribute to the development of breast cancer will …

Context Time spent in sedentary behaviours (SB) is associated with poor health, irrespective
of the level of physical activity. The aim of this study was to evaluate the effect of …

Background The global prevalence of childhood and adolescent obesity is high. Lifestyle
changes towards a healthy diet, increased physical activity and reduced sedentary activities …

Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a
manageable safety profile in studies of phase 1 and 2 in patients with BRAF V600-mutated …

Background The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as
monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E …

Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are
found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy …

Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

Background Brain metastases are common in patients with metastatic melanoma and
median overall survival from their diagnosis is typically 17–22 weeks. We assessed …

Purpose The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and
cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three …

Purpose Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our
multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib …